152 related articles for article (PubMed ID: 12824031)
21. The novel phosphodiesterase 4 inhibitor, CI-1044, inhibits LPS-induced TNF-alpha production in whole blood from COPD patients.
Ouagued M; Martin-Chouly CA; Brinchault G; Leportier-Comoy C; Depincé A; Bertrand C; Lagente V; Belleguic C; Pruniaux MP
Pulm Pharmacol Ther; 2005; 18(1):49-54. PubMed ID: 15607127
[TBL] [Abstract][Full Text] [Related]
22. Orally active indole N-oxide PDE4 inhibitors.
Hulme C; Mathew R; Moriarty K; Miller B; Ramanjulu M; Cox P; Souness J; Page KM; Uhl J; Travis J; Labaudiniere R; Huang F; Djuric SW
Bioorg Med Chem Lett; 1998 Nov; 8(21):3053-8. PubMed ID: 9873675
[TBL] [Abstract][Full Text] [Related]
23. Comparison of inhibition of ovalbumin-induced bronchoconstriction in guinea pigs and in vitro inhibition of tumor necrosis factor-alpha formation with phosphodiesterase 4 (PDE4) selective inhibitors.
Muise ES; Chute IC; Claveau D; Masson P; Boulet L; Tkalec L; Pon DJ; Girard Y; Frenette R; Mancini JA
Biochem Pharmacol; 2002 Apr; 63(8):1527-35. PubMed ID: 11996895
[TBL] [Abstract][Full Text] [Related]
24. Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel binding affinity.
Friesen RW; Ducharme Y; Ball RG; Blouin M; Boulet L; Côté B; Frenette R; Girard M; Guay D; Huang Z; Jones TR; Laliberté F; Lynch JJ; Mancini J; Martins E; Masson P; Muise E; Pon DJ; Siegl PK; Styhler A; Tsou NN; Turner MJ; Young RN; Girard Y
J Med Chem; 2003 Jun; 46(12):2413-26. PubMed ID: 12773045
[TBL] [Abstract][Full Text] [Related]
25. N-arylrolipram derivatives as potent and selective PDE4 inhibitors.
Bacher E; Boer C; Bray-French K; Demnitz FW; Keller TH; Mazzoni L; Müller T; Walker C
Bioorg Med Chem Lett; 1998 Nov; 8(22):3229-34. PubMed ID: 9873708
[TBL] [Abstract][Full Text] [Related]
26. Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.
Burnouf C; Auclair E; Avenel N; Bertin B; Bigot C; Calvet A; Chan K; Durand C; Fasquelle V; Féru F; Gilbertsen R; Jacobelli H; Kebsi A; Lallier E; Maignel J; Martin B; Milano S; Ouagued M; Pascal Y; Pruniaux MP; Puaud J; Rocher MN; Terrasse C; Wrigglesworth R; Doherty AM
J Med Chem; 2000 Dec; 43(25):4850-67. PubMed ID: 11123995
[TBL] [Abstract][Full Text] [Related]
27. Anti-inflammatory and utero-relaxant effects in human myometrium of new generation phosphodiesterase 4 inhibitors.
Oger S; Méhats C; Barnette MS; Ferré F; Cabrol D; Leroy MJ
Biol Reprod; 2004 Feb; 70(2):458-64. PubMed ID: 14561639
[TBL] [Abstract][Full Text] [Related]
28. Discovery of new orally active phosphodiesterase (PDE4) inhibitors.
Ochiai H; Ishida A; Ohtani T; Kusumi K; Kishikawa K; Yamamoto S; Takeda H; Obata T; Nakai H; Toda M
Chem Pharm Bull (Tokyo); 2004 Sep; 52(9):1098-104. PubMed ID: 15340197
[TBL] [Abstract][Full Text] [Related]
29. Thalidomide analogs and PDE4 inhibition.
Muller GW; Shire MG; Wong LM; Corral LG; Patterson RT; Chen Y; Stirling DI
Bioorg Med Chem Lett; 1998 Oct; 8(19):2669-74. PubMed ID: 9873600
[TBL] [Abstract][Full Text] [Related]
30. 7-Methoxybenzofuran-4-carboxamides as PDE 4 inhibitors: a potential treatment for asthma.
Buckley G; Cooper N; Dyke HJ; Galleway F; Gowers L; Gregory JC; Hannah DR; Haughan AF; Hellewell PG; Kendall HJ; Lowe C; Maxey R; Montana JG; Naylor R; Picken CL; Runcie KA; Sabin V; Tuladhar BR; Warneck JB
Bioorg Med Chem Lett; 2000 Sep; 10(18):2137-40. PubMed ID: 10999488
[TBL] [Abstract][Full Text] [Related]
31. Dissecting the cofactor-dependent and independent bindings of PDE4 inhibitors.
Liu S; Laliberté F; Bobechko B; Bartlett A; Lario P; Gorseth E; Van Hamme J; Gresser MJ; Huang Z
Biochemistry; 2001 Aug; 40(34):10179-86. PubMed ID: 11513595
[TBL] [Abstract][Full Text] [Related]
32. Evidence that cyclic AMP phosphodiesterase inhibitors suppress TNF alpha generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer.
Souness JE; Griffin M; Maslen C; Ebsworth K; Scott LC; Pollock K; Palfreyman MN; Karlsson JA
Br J Pharmacol; 1996 Jun; 118(3):649-58. PubMed ID: 8762090
[TBL] [Abstract][Full Text] [Related]
33. Phthalazine PDE4 inhibitors. Part 2: the synthesis and biological evaluation of 6-methoxy-1,4-disubstituted derivatives.
Napoletano M; Norcini G; Pellacini F; Marchini F; Morazzoni G; Ferlenga P; Pradella L
Bioorg Med Chem Lett; 2001 Jan; 11(1):33-7. PubMed ID: 11140727
[TBL] [Abstract][Full Text] [Related]
34. Syntheses and evaluation of pyrido[2,3-dlpyrimidine-2,4-diones as PDE 4 inhibitors.
Nam G; Yoon CM; Kim E; Rhee CK; Kim JH; Shin JH; Kim SH
Bioorg Med Chem Lett; 2001 Mar; 11(5):611-4. PubMed ID: 11266153
[TBL] [Abstract][Full Text] [Related]
35. Effects of inhibition of PDE4 and TNF-alpha on local and remote injuries following ischaemia and reperfusion injury.
Souza DG; Cassali GD; Poole S; Teixeira MM
Br J Pharmacol; 2001 Nov; 134(5):985-94. PubMed ID: 11682446
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis and structure-activity relationships of a series of 9-substituted adenine derivatives as selective phosphodiesterase type-4 inhibitors.
Raboisson P; Lugnier C; Muller C; Reimund JM; Schultz D; Pinna G; Le Bec A; Basaran H; Desaubry L; Gaudiot F; Seloum M; Bourguignon JJ
Eur J Med Chem; 2003 Feb; 38(2):199-214. PubMed ID: 12620664
[TBL] [Abstract][Full Text] [Related]
37. Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-[2-(3,4-Bisdifluromethoxyphenyl)-2-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl]3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor.
Claveau D; Chen SL; O'Keefe S; Zaller DM; Styhler A; Liu S; Huang Z; Nicholson DW; Mancini JA
J Pharmacol Exp Ther; 2004 Aug; 310(2):752-60. PubMed ID: 15082748
[TBL] [Abstract][Full Text] [Related]
38. Antidepressant-like effects of PDE4 inhibitors mediated by the high-affinity rolipram binding state (HARBS) of the phosphodiesterase-4 enzyme (PDE4) in rats.
Zhang HT; Zhao Y; Huang Y; Deng C; Hopper AT; De Vivo M; Rose GM; O'Donnell JM
Psychopharmacology (Berl); 2006 Jun; 186(2):209-17. PubMed ID: 16586089
[TBL] [Abstract][Full Text] [Related]
39. Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages.
Jin SL; Lan L; Zoudilova M; Conti M
J Immunol; 2005 Aug; 175(3):1523-31. PubMed ID: 16034090
[TBL] [Abstract][Full Text] [Related]
40. Synthesis of pyrrolo[2,3-d]pyridazinones as potent, subtype selective PDE4 inhibitors.
Giovannoni MP; Cesari N; Graziano A; Vergelli C; Biancalani C; Biagini P; Dal Piaz V
J Enzyme Inhib Med Chem; 2007 Jun; 22(3):309-18. PubMed ID: 17674813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]